Mineralys Therapeutics, Inc. MLYS
25.86
(0.73)
(2.75%)
as of 25 Sep
- Market cap
- $2.4B
- P/E
- 0.0×
Follow MLYS
Insider Buys
alert about insiders buying in the last 12 month
| Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|
Current Ratio |
0.29 | 2.20 | 13.98 | 23.76 | 14.02 | 43.76 |
Net Debt/EBITDA |
0.48 | 0.57 | 3.50 | 2.79 | 1.03 | 3.85 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.72 | 0.75 | 0.98 | 1.13 | 0.94 | 0.92 |
Capex/Depreciation |
— | — | — | — | (2.23) | (0.25) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 0.00% | 146.35% | 79.26% | (76.13%) | (82.24%) | (36.91%) | |
| 0.00% | (307.79%) | (47.46%) | (39.28%) | (77.72%) | (35.65%) | |
ROIC |
0.00% | 0.00% | 0.00% | (1,153.49%) | 0.00% | 0.00% |
Return on Tangible Assets |
94.72% | (319.84%) | (28.45%) | (30.13%) | (93.21%) | (23.93%) |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(0.53) | (2.92) | (5.66) | (2.24) | (3.43) | (2.11) |
Cash per Share |
0.30 | 2.13 | 21.31 | 6.54 | 4.08 | 9.71 |
Shareholders Equity per Share |
(0.78) | (4.60) | (10.12) | 6.66 | 3.94 | 9.56 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(0.78) | (4.60) | (10.12) | 6.66 | 3.94 | 9.56 |
Free Cash Flow |
(2.46) | (14.56) | (29.22) | (81.17) | (166.41) | (142.43) |
Working Capital |
(3.62) | 6.07 | 104.74 | 238.62 | 190.71 | 646.27 |
Capital Expenditures |
— | — | — | — | (0.10) | (0.01) |
Net Current Asset Value |
(3.62) | (22.93) | (53.90) | 238.62 | 190.71 | 646.27 |
| Other line items | ||||||
Quick Ratio |
0.28 | 2.10 | 13.65 | 22.57 | 13.53 | 43.45 |
Depreciation/Fixed assets |
— | — | — | — | 0.81 | 1.55 |
Cash ROIC |
112.57% | 118.24% | (50.52%) | (16.99%) | (42.72%) | (10.93%) |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.53) | (2.92) | (5.66) | (2.24) | (3.43) | (2.10) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Payables |
— | 0.65 | 1.34 | 1.25 | 0.54 | 1.25 |
Average Assets |
— | 6.31 | 62.78 | 183.04 | 228.77 | 433.85 |
Average Common Equity |
— | (13.26) | (37.60) | 94.44 | 216.21 | 418.98 |
Capex to Sales |
— | — | — | — | 0.00 | 0.00 |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates